Bruker Stock (NASDAQ:BRKR), Trade Ideas

Bruker

Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, pharmaceutical, and biotechnology industries. It operates in four operating segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from Asia Pacific.

Worst Performing

BBVA

BRKR

DASH

GEHC

MSTR

SBUX

SMCI

STLA

SWKS

15 large-cap stocks had a rough week, with CVS, Starbucks, and DoorDash all taking major hits. Analysts have lowered price targets on many.

Last Week&#39;s Worst-Performing Stocks: Are These 15 Large-Cap Stocks In Your Portfolio? (April 28-May 4, 2024)

Red,Stock,Market,Price,Showing,Trader,Phobia,Of,Crisis,War

News

Movers

ANET

ASML

COIN

JBHT

TSLA

Last week&#39;s worst performers included Arm Holdings, Coinbase Global, Live Nation Entertainment and J.B. Hunt Transport Services.

Last Week&#39;s Worst-Performing Stocks: Are These 11 Large-Cap Stocks In Your Portfolio? (April 14-20, 2024)

Price Target

Small Cap

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

BIIB

CRWD

DENN

KALV

SHOP

SSNC

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Citigroup To Rally Over 19%? Here Are 10 Top Analyst Forecasts For Wednesday

Bruker Corp

Legal

Global

German Federal Patent Court Invalidates European Patent No. 2794928B1 In Germany

NanoString, now a Bruker business, will promptly seek an end to the injunction impacting sales of CosMx SMI products in Germany
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bruker.com&amp;esheet=53977100&amp;newsitemid=20240507563533&amp;lan=en-US&amp;anchor=Bruker+Corporation&amp;index=1&amp;md5=4c5082ca5ae77a72a52a4eac7e40cb58">Bruker Corporation</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) today announced that the German Federal Patent Court has ruled in favor of NanoString Technologies Germany GmbH by invalidating European Patent No. 2794928B1 (the "928 Patent") in Germany (case 3 Ni 20/22). NanoString is now a Bruker business following Bruker's asset acquisition of the businesses of NanoString Technologies, Inc on May 6th, 2024. The 928 Patent has been asserted by 10x Genomics against NanoString in patent infringement cases in Germany and before the European Unified Patent Court (UPC) involving NanoString's CosMx Spatial Molecular Imager (SMI) products for RNA detection. The Federal Patent Court ruled that the German part of the 928 Patent is invalid.
"NanoString has consistently maintained that the patents being asserted by 10x Genomics against NanoString's CosMx SMI products are invalid. Today's ruling of the German Federal Patent Court is a decisive victory for NanoString and Bruker and a resounding vindication of NanoString's belief from the outset that these cases are without merit. This ruling is also a win for science and enables a re-leveling of the playing field in the research tools industry in Germany," commented Dr. Mark R. Munch, President of the Bruker NANO Group.
Today's decision in Germany follows NanoString's win before the UPC Court of Appeal in Luxembourg in February on a related patent. In that case, the Court overturned a preliminary injunction that had previously been issued by a lower court based on the closely related European Patent 4108782B1 (the "782 Patent"). The UPC Court of Appeal noted in its February ruling that it was likely "that the patent at issue will not prove to be valid," citing concerns about the obviousness of the patent claims based on the prior art. Today's decision of the German Federal Patent Court is in line with that separate court's analysis.
"Today's win is further evidence of the turning of the tide in our favor in these cases," Dr. Munch added. "Bruker expects to build on this significant legal victory and to further fight for scientific freedom."
Following today's win, NanoString will promptly ask the German Higher Regional Court of Munich to permanently lift the injunction impacting NanoString's CosMx products and the scientists who rely on them in Germany. In December 2023, the German Higher Regional Court of Munich cited concerns with the lower Munich Regional Court's May 2023 decision and granted NanoString the right to have the injunction on sales of CosMx products in Germany lifted, subject to payment of a bond. NanoString also expects to have its attorneys' fees and related legal expenses reimbursed in light of today's ruling.

German Federal Patent Court Invalidates Patent Asserted By 10x Genomics, Delivering Legal Win To NanoString, Now A Bruker Business, Will Seek An End To The Injunction Impacting Sales Of CosMx SMI Products In Germany

These 15 large-cap stocks were the worst performers last week. Are they in your portfolio?
<ol>
<li>CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) shares tumbled 18.2% after it reported first-quarter sales of $88.4 billion, missing the consensus of $89.21 billion, and adjusted EPS of $1.31 <a href="https://www.benzinga.com//node/38549660" target="_blank" rel="noreferrer noopener">missed the consensus of $1.69m and cut FY24 guidance</a>. Several analysts <a href="https://www.benzinga.com//node/38582839" target="_blank" rel="noreferrer noopener">trimmed the price target</a>.</li>
<li>Skyworks Solutions, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKS#NASDAQ">SWKS</a>) shares plummeted 16.8% after the company reported&nbsp;Q2&nbsp;financial results and issued&nbsp;Q3&nbsp;revenue&nbsp;guidance&nbsp;with&nbsp;<a target="_blank" href="https://www.benzinga.com//node/38536220" rel="noreferrer noopener">the midpoint below estimates</a>. Several analysts cut the&nbsp;<a target="_blank" href="https://www.benzinga.com//node/38549218" rel="noreferrer noopener">price target on the stock</a>.</li>
<li>Starbucks Corporation&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) shares decreased 15.2% following worse-than-expected earnings&nbsp;<a target="_blank" href="https://www.benzinga.com//node/38534321" rel="noreferrer noopener">results for the&nbsp;second quarter of FY24</a>. Multiple analysts lowered price targets on the&nbsp;<a target="_blank" href="https://www.benzinga.com//node/38549288" rel="noreferrer noopener">stock&nbsp;following the release</a>.</li>
<li>Super Micro Computer, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) shares are down 14.4% after the company posted mixed&nbsp;<a target="_blank" href="https://www.benzinga.com//node/38555359" rel="noreferrer noopener">third-quarter&nbsp;financial results</a>. Few analysts cut and&nbsp;<a target="_blank" href="https://www.benzinga.com/quote/SMCI/analyst-ratings" rel="noreferrer noopener">boosted the price target</a>.</li>
<li>Bruker Corporation&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) shares decreased 13.8% after the company&nbsp;<a target="_blank" href="https://www.benzinga.com//node/38577397" rel="noreferrer noopener">reported&nbsp;Q1&nbsp;revenue miss</a>.</li>
<li>Stellantis N.V.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STLA#NYSE">STLA</a>) shares declined 13.5% after the company reported&nbsp;a&nbsp;12%&nbsp;decrease in first-quarter&nbsp;net revenues and&nbsp;<a target="_blank" href="https://www.benzinga.com//node/38515774" rel="noreferrer noopener">a&nbsp;10%&nbsp;reduction in consolidated shipments</a>.&nbsp;</li>
<li>DoorDash, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) shares declined 13.5% after the company reported&nbsp;<a target="_blank" href="https://www.benzinga.com//node/38565879" rel="noreferrer noopener">mixed&nbsp;Q1&nbsp;financial results</a>. Most analysts trimmed the&nbsp;<a target="_blank" href="https://www.benzinga.com/quote/dash/analyst-ratings" rel="noreferrer noopener">price target on the stock</a>.</li>
<li>Centrais Electricas Brasileiras&nbsp;S.A.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBR#NYSE">EBR</a>) shares were down 13.5%.</li>
<li>MicroStrategy Incorporated&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) shares dived 12.7% after the company&nbsp;<a target="_blank" href="https://www.benzinga.com//node/38503135" rel="noreferrer noopener">reported&nbsp;Q1&nbsp;financial results</a>.</li>
<li>GE&nbsp;HealthCare&nbsp;Technologies Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEHC#NASDAQ">GEHC</a>) shares declined 12.5% after it reported&nbsp;first-quarter&nbsp;sales of&nbsp;$4.6 billion, which&nbsp;<a target="_blank" href="https://www.benzinga.com//node/38525477" rel="noreferrer noopener">missed the&nbsp;consensus of&nbsp;$4.8 billion</a>. Some analysts&nbsp;<a target="_blank" href="https://www.benzinga.com/quote/gehc/analyst-ratings" rel="noreferrer noopener">reduced the price target</a>.</li>
<li>The Carlyle Group Inc.&nbsp;(NASDAQ:&nbsp;CG) shares decreased 12.4% after the company reported&nbsp;Q1&nbsp;financial results.</li>
<li>Global Payments Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPN#NYSE">GPN</a>) shares were down 11.3% after it reported&nbsp;Q1&nbsp;financial&nbsp;<a target="_blank" href="https://www.benzinga.com//node/38558593" rel="noreferrer noopener">results and issued&nbsp;guidance</a>.</li>
<li>Banco Bilbao Vizcaya Argentaria S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBVA#NYSE">BBVA</a>) shares declined 11.3% after reporting first-quarter FY24 results. The company reportedly confirmed its intention to start talks with Sabadell on a potential merger.</li>
<li>CDW Corporation&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDW#NASDAQ">CDW</a>) shares declined 11.2%&nbsp;after the company reported worse-than-<a target="_blank" href="https://www.benzinga.com//node/38559196" rel="noreferrer noopener">expected&nbsp;Q1&nbsp;financial results</a>. Analysts trimmed&nbsp;<a target="_blank" href="https://www.benzinga.com//node/38559196" rel="noreferrer noopener">the price target on the stock</a>.</li>
<li>APA Corporation&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APA#NASDAQ">APA</a>) shares are down 10.8% after it reported worse-than-expected&nbsp;Q1&nbsp;earnings and&nbsp;<a target="_blank" href="https://www.benzinga.com//node/38564165" rel="noreferrer noopener">APA revised FY24&nbsp;guidance</a>.&nbsp;</li>
</ol>
Also Read: <a href="https://www.benzinga.com/markets/equities/24/05/38633878/which-large-cap-stocks-are-winning-this-earnings-season-15-stocks-to-watch-april-28-may-4-2024">Which Large Cap Stocks Are Winning This Earnings Season: 15 Stocks To Watch (April 28-May 4, 2024)</a>
Photo: Shutterstock

Last Week's Worst-Performing Stocks: Are These 15 Large-Cap Stocks In Your Portfolio? (April 28-May 4, 2024)

<h3>Gainers</h3>
<ul>
<li>Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) stock moved upwards by 98.4% to $3.83 during Thursday's regular session. The company's market cap stands at $200.6 million. The company's, Q1 earnings came out yesterday. </li>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) stock moved upwards by 40.1% to $0.19. The market value of their outstanding shares is at $1.2 million. </li>
<li>Sensei Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNSE#NASDAQ">SNSE</a>) shares increased by 40.05% to $1.76. The company's market cap stands at $44.2 million. </li>
<li>Syra Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRA#NASDAQ">SYRA</a>) shares rose 36.26% to $1.42. The company's market cap stands at $9.3 million. </li>
<li>Jaguar Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) shares moved upwards by 32.35% to $0.3. The company's market cap stands at $85.5 million. </li>
<li>Titan Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTNP#NASDAQ">TTNP</a>) shares moved upwards by 25.37% to $8.4. The market value of their outstanding shares is at $7.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Accuray (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAY#NASDAQ">ARAY</a>) shares fell 27.6% to $1.57 during Thursday's regular session. The market value of their outstanding shares is at $155.6 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Metagenomi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGX#NASDAQ">MGX</a>) shares fell 17.62% to $5.8. The market value of their outstanding shares is at $217.3 million. </li>
<li>Elevation Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELEV#NASDAQ">ELEV</a>) stock fell 11.26% to $3.55. The company's market cap stands at $172.7 million. The company's, Q1 earnings came out today. </li>
<li>Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) stock fell 11.13% to $70.24. The company's market cap stands at $10.2 billion. As per the news, the Q1 earnings report came out today. </li>
<li>Ocean Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) stock fell 10.97% to $1.34. The company's market cap stands at $46.4 million. </li>
<li>BioAtla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAB#NASDAQ">BCAB</a>) stock declined by 10.84% to $3.0. The market value of their outstanding shares is at $144.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARAY

BCAB

ELEV

JAGX

NUWE

OCEA

SNSE

SYRA

TTNP

12 Health Care Stocks Moving In Thursday's Intraday Session

WIIM

Bruker shares are trading lower after a Q1 revenue miss.

Fiscal Year 2024 Financial&nbsp;Outlook
Bruker&#39;s FY 2024 updated&nbsp;guidance&nbsp;now includes the expected benefits of the Chemspeed acquisition closed in&nbsp;Q1&nbsp;2024, and of the ELITech acquisition, which closed on April 30, 2024. Our updated FY 2024&nbsp;guidance&nbsp;does not include the pending, EPS-dilutive NanoString acquisition, announced by Bruker on April 22, 2024, and expected to close in&nbsp;Q2-24.
Bruker now expects FY 2024 revenues of&nbsp;$3.29&nbsp;to&nbsp;$3.35 billion, up&nbsp;$60 million&nbsp;from our prior&nbsp;guidance&nbsp;of&nbsp;$3.23&nbsp;to&nbsp;$3.29 billion. Bruker&#39;s updated FY 2024 revenue&nbsp;guidance&nbsp;implies&nbsp;11%&nbsp;to&nbsp;13%&nbsp;year-over-year reported revenue growth, up from our prior&nbsp;guidance&nbsp;of&nbsp;9%&nbsp;to&nbsp;11%, and including yoy contributions from:
<ul>
<li>Organic revenue growth of&nbsp;5%&nbsp;to&nbsp;7%, no change from prior&nbsp;guidance</li>
<li>Constant exchange rate (CER) revenue growth of&nbsp;12%&nbsp;to&nbsp;14%, up 400 bps vs. prior&nbsp;guidance, and reflecting all closed acquisitions, including Chemspeed and ELITech</li>
<li>Foreign currency translation headwind of&nbsp;-1%, vs. prior expectation of a&nbsp;+1%&nbsp;tailwind.</li>
</ul>
Bruker now expects FY 2024 non-GAAP EPS of&nbsp;$2.79&nbsp;to&nbsp;$2.84, up 8 cents from our prior&nbsp;guidance&nbsp;of&nbsp;$2.71&nbsp;to&nbsp;$2.76, and excluding the estimated impact of the pending dilutive NanoString acquisition.
Bruker&#39;s updated FY 2024 revenue and non-GAAP EPS&nbsp;guidance&nbsp;is based on foreign currency exchange rates as of March 31, 2024.

Earnings

Guidance

Bruker Updates 2024 Outlook: Now Sees Revenue Of $3.29B-$3.35B (Prior  $3.23B-$3.29B) Vs. $3.282B Est.; Sees Adjusted EPS Of $2.79 To $2.84 (Prior $2.71-$2.76) Vs. $2.71 Est.

Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) reported quarterly earnings of $0.53 per share which beat the analyst consensus estimate of $0.46 by 15.22 percent. This is a 17.19 percent decrease over earnings of $0.64 per share from the same period last year. The company reported quarterly sales of $721.700 million which missed the analyst consensus estimate of $729.879 million by 1.12 percent. This is a 5.31 percent increase over sales of $685.300 million the same period last year.

Earnings Beats

Earnings Misses

Bruker Q1 2024 Adj EPS $0.53 Beats $0.46 Estimate, Sales $721.700M Miss $729.879M Estimate

Bruker shares are trading higher amid strength in life sciences tools stocks following strong earnings from Danaher and strong guidance from Medpace.

These seven large-cap stocks were the worst performers last week. Are they in your portfolio?
<ol>
<li>Arm Holdings plc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) was the worst large-cap stock performer last week, plummeting 31.08%. The company fell alongside ASML Holding N.V.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>), which reported worse-than-expected&nbsp;<a href="https://www.benzinga.com/news/24/04/38299189/whats-going-on-with-arm-holdings-stock" target="_blank" rel="noreferrer noopener">first-quarter FY24 results last week</a>. Exane BNP Paribas analyst David O&#8217;Connor downgraded ARM from&nbsp;<a href="https://www.benzinga.com/quote/ARM/analyst-ratings" target="_blank" rel="noreferrer noopener">&#8220;Outperform&#8221; to &#8220;Neutral&#8221;</a> with a $100 price target.</li>
<li>MicroStrategy Inc&#8217;s&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) stock lost 20.07% last week. Most crypto stocks fell last week due to the volatility in Bitcoin (CRYPTO: BTC/USD) price.</li>
<li>Coinbase Global Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) stock lost 15% last week due to weakness in Bitcoin&#8217;s (CRYPTO: BTC/USD) price. Economist and crypto skeptic Peter Schiff&nbsp;<a target="_blank" href="https://www.benzinga.com//node/38265256" rel="noreferrer noopener">expressed skepticism</a>&nbsp;regarding the apex crypto blasting off in line with predictions by some bulls.</li>
<li>Prologis, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLD#NYSE">PLD</a>) declined 13.73% as the company&#8217;s first quarter FY24 rental revenue of $1.83 billion missed the consensus and lowered the FY24 outlook for EPS and core FFO/share due to anticipated lower&nbsp;<a href="https://www.benzinga.com/news/earnings/24/04/38292399/why-prologis-shares-are-trading-lower-today" target="_blank" rel="noreferrer noopener">average occupancy and competitive leasing</a>.</li>
<li>Tesla Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) fell 13.6% last week. The Elon Musk-led company had a tough week on&nbsp;<a href="https://www.benzinga.com//node/38346490" target="_blank" rel="noreferrer noopener">multiple counts</a>. It faces falling EV demand, a Cybertruck recall, employee layoffs, and price cuts.</li>
<li>Equifax Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFX#NYSE">EFX</a>) stock decreased 13.54%. The company reported worse-than-expected first-quarter sales results and issued adjusted&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/24/04/38333254/equifax-analysts-cut-their-forecasts-after-q1-results" rel="noreferrer noopener">guidance below estimates on Wednesday</a>.</li>
<li>Bruker Corp&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) has had a tough week, losing 11.90% in value after announcing NanoString Technologies&#8217;s acquisition&nbsp;for $392.6 million in cash.</li>
<li>Live Nation Entertainment, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>) was down 11.76%. The company&#8217;s shares took a hit following a report indicating the Justice Department will file an antitrust&nbsp;<a target="_blank" href="https://www.benzinga.com/news/24/04/38265894/live-nation-entertainment-groupon-and-other-big-stocks-moving-lower-in-tuesdays-pre-market-session" rel="noreferrer noopener">lawsuit against the company</a>.</li>
<li>Arista Networks Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>) fell 10.69% last week. Recently, a Rosenblatt analyst&nbsp;<a href="https://www.benzinga.com//node/38220808" target="_blank" rel="noreferrer noopener">double-downgraded the stock to &#8220;Sell&#8221;</a>&nbsp;with a $210 price target.</li>
<li>J.B. Hunt Transport Services, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBHT#NASDAQ">JBHT</a>) fell 10.47% as its first-quarter FY24 earnings missed consensus estimates due to lower segment&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/24/04/38287679/why-j-b-hunt-transport-shares-are-diving-today" rel="noreferrer noopener">gross revenue and fewer loads</a>. Several analysts lowered&nbsp;<a target="_blank" href="https://www.benzinga.com/quote/JBHT/analyst-ratings" rel="noreferrer noopener">price targets on the stock</a>&nbsp;following the earnings miss.</li>
<li>Albemarle Corp&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALB#NYSE">ALB</a>) stock shed 9% in value last week due to lithium price volatility.</li>
</ol>
See Also: <a href="https://www.benzinga.com/news/earnings/24/04/38349264/tracking-last-weeks-top-performers-are-these-7-large-cap-stocks-in-your-portfolio">Tracking Last Week&#8217;s Top Performers: Are These 7 Large-Cap Stocks In Your Portfolio?</a>
Photo: Shutterstock

Last Week's Worst-Performing Stocks: Are These 11 Large-Cap Stocks In Your Portfolio? (April 14-20, 2024)

Following the closing, NanoString&#39;s business operations will no longer be the subject of a chapter 11 proceeding and will be owned by Bruker on a go-forward basis.&nbsp;The transaction was agreed to under a court-supervised chapter 11 sale process pursuant to Section 363 of the U.S. Bankruptcy Code and is expected to close in early-May 2024.&nbsp;

NanoString Technologies To Be Acquired By Bruker For ~$392.6M In Cash Consideration, Plus Assumption Of Certain Liabilities; Bruker Wins Competitive Auction

Goldman Sachs analyst Matthew Sykes maintains Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) with a Sell and raises the price target from $66 to $74.

Goldman Sachs Maintains Sell on Bruker, Raises Price Target to $74

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bruker.com&amp;esheet=53923608&amp;newsitemid=20240408860289&amp;lan=en-US&amp;anchor=Bruker+Corporation&amp;index=1&amp;md5=b0d1a1534e25f9515d1a0faacf0a0c7e">Bruker Corporation</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>), the leading provider of nuclear magnetic resonance (NMR) spectroscopy solutions, announces the introduction of novel high-resolution solid-state NMR scientific capabilities that can enable unprecedented structural biology discoveries in large proteins, membrane proteins and in protein aggregates.

Bruker Introduces NMR Scientific Capabilities for Structural Biology Discoveries in Membrane Proteins and Protein Aggregates

<ul>
<li>Strategic partnership expands Biognosys' services to include Alamar's NULISA assays as well as joint scientific research in biofluid-based proteomics</li>
<li>Complementary value of Biognosys' DIA-MS unbiased proteomics platform and Alamar's game-changing immunoassay platforms to be presented at the AACR 2024 Annual Meeting</li>
</ul>

Contracts

Biognosys, Alamar Biosciences Forge Strategic Partnership In Proteomics

Health Care

General

Bruker Advances CCS-Enabled 4D-Proteomics TimsTOF Solutions for Immunopeptidomes and Glycoproteomics At US Human Proteome Organization Congress 2024

UBS analyst John Sourbeer maintains Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) with a Buy and raises the price target from $94 to $102.

UBS Maintains Buy on Bruker, Raises Price Target to $102

As reported in an 8-K SEC filing on December 26, 2023, Bruker had previously entered into a put option agreement with the sellers, pending workers&#39; council consultations in France and The Netherlands.&nbsp;Bruker expects to close the transaction in the&nbsp;second quarter&nbsp;of 2024.&nbsp;ELITechGroup, excluding the clinical chemistry business, achieved approximately &euro;150 million in revenues in 2023.

Bruker Inks Share Purchase Agreement To Acquire Molecular Diagnostics Company ELITechGroup; Deal Value €870 M Cash, Excluding Carved Out ELITech Clinical Chemistry Business

UBS has decided to maintain its Buy rating of Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) and raise its price target from $86.00 to $94.00.
Shares of Bruker are trading down 0.8% over the last 24 hours, at $79.41 per share.
A move to $94.00 would account for a 18.37% increase from the current share price.
<h3>About Bruker</h3>
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, pharmaceutical, and biotechnology industries. It operates in four operating segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano and Bruker Energy and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives a majority of its revenue from Europe.
<h3>About Analyst Ratings</h3>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along with analyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

UBS Maintains Buy Rating for Bruker: Here's What You Need To Know

<a href="https://www.sec.gov/Archives/edgar/data/1649339/000090514824000653/xslForm13F_X02/informationtable.xml" title="https://www.sec.gov/Archives/edgar/data/1649339/000090514824000653/xslForm13F_X02/informationtable.xml">https://www.sec.gov/Archives/edgar/data/1649339/000090514824000653/xslForm13F_X02/informationtable.xml</a>

AMZN

GOOGL

ORCL

VTLE

Scion Asset Management, LLC 13F Filing Raises Stake In HCA Healthcare By 20K; Raises Stake In Oracle By 50K; Raises Stake In Citigroup By 100K; Raises Stake In CVS Health Corp By 65K; Raises Stake In Alphabet By 35K; Raises Stake In Amazon.com By 30K; Raises Stake In Advance Auto Parts By 70K; Raises Stake In Vital Energy By 87.5K; Raises Stake In Block By 50K; Raises Stake In Bruker By 50K

Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Bruker and provided 12-month price targets. The average target is $84.5, accompanied by a high estimate of $95.00 and a low estimate of $72.00. This upward trend is evident, with the current average reflecting a 24.87% increase from the previous average price target of $67.67.
<img src="https://www.benzinga.com/files/images/story/2024/1707933637_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The perception of Bruker by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$95.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Daniel Arias</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$81.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Tycho Peterson</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Timothy Daley</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$72.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Bruker. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Bruker compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
To gain a panoramic view of Bruker's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/BRKR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Bruker analyst ratings.</a>
<h2>Discovering Bruker: A Closer Look</h2>
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, pharmaceutical, and biotechnology industries. It operates in four operating segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano and Bruker Energy and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives a majority of its revenue from Europe.
<h3>Financial Insights: Bruker</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Bruker's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2023, the company achieved a revenue growth rate of approximately 16.26%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Bruker's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 11.86%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 7.22%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Bruker's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.3%, the company showcases efficient use of assets and strong financial health.
Debt Management: Bruker's debt-to-equity ratio stands notably higher than the industry average, reaching 1.01. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Unveiling 4 Analyst Insights On Bruker

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-ratings/">analyst ratings page</a>.
<ul>
<li>Keybanc raised the price target for CrowdStrike Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crwd#NASDAQ">CRWD</a>) from $318 to $375. Keybanc analyst Eric Heath maintained an Overweight rating. CrowdStrike shares rose 0.4% to close at $322.44 on Tuesday. <a href="https://www.benzinga.com/quote/CRWD/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Piper Sandler boosted Shopify Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/shop#NYSE">SHOP</a>) price target from $56 to $63. Piper Sandler analyst Clarke Jeffries maintained an Underweight rating. Shopify shares fell 13.4% to close at $77.18 on Tuesday. <a href="https://www.benzinga.com/quote/SHOP/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham boosted the price target for SS&amp;C Technologies Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ssnc#NASDAQ">SSNC</a>) from $62 to $70. Needham analyst Mayank Tandon maintained a Buy rating. SS&amp;C Technologies shares fell 1.8% to close at $60.15 on Tuesday. <a href="https://www.benzinga.com/quote/SSNC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JP Morgan raised Bruker Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/brkr#NASDAQ">BRKR</a>) price target from $60 to $90. JP Morgan analyst Tycho Peterson upgraded the stock from Neutral to Overweight. Bruker shares jumped 8.8% to close at $76.79 on Tuesday. <a href="https://www.benzinga.com/quote/BRKR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HSBC increased the price target for HP Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hpq#NYSE">HPQ</a>) from $30 to $33. HSBC analyst Stephen Bersey upgraded the stock from Hold to Buy. HP shares fell 1.9% to close at $28.14 on Tuesday. <a href="https://www.benzinga.com/quote/HPQ/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler raised the price target for Citigroup Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/c#NYSE">C</a>) from $56 to $63. Piper Sandler analyst Scott Siefers upgraded the stock from Neutral to Overweight. Citigroup shares fell 2.2% to close at $52.76 on Tuesday. <a href="https://www.benzinga.com/quote/C/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. increased KalVista Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kalv#NASDAQ">KALV</a>) price target from $16 to $24. HC Wainwright &amp; Co. analyst Andrew Fein maintained a Buy rating. KalVista Pharmaceuticals shares fell 7.4% to close at $14.85 on Tuesday. <a href="https://www.benzinga.com/quote/KALV/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wedbush cut Denny&#39;s Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/denn#NASDAQ">DENN</a>) price target from $11 to $10.5. Wedbush analyst Nick Setyan maintained a Neutral rating. Denny&#39;s shares fell 4.2% to close at $9.91 on Tuesday. <a href="https://www.benzinga.com/quote/DENN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham cut Biogen Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/biib#NASDAQ">BIIB</a>) price target from $305 to $300. Needham analyst Ami Fadia maintained a Buy rating. Biogen shares fell 7.4% to close at $226.65 on Tuesday. <a href="https://www.benzinga.com/quote/BIIB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keybanc boosted MongoDB, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mdb#NASDAQ">MDB</a>) price target from $500 to $543. Keybanc analyst Eric Heath maintained an Overweight rating. MongoDB shares fell 3.3% to close at $472.13 on Tuesday. <a href="https://www.benzinga.com/quote/MDB/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
&nbsp;
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/02/37116775/kraft-heinz-lyft-and-3-stocks-to-watch-heading-into-wednesday"> Kraft Heinz, Lyft And 3 Stocks To Watch Heading Into Wednesday </a>

Bruker Corporation: An Aggressive Acquisition Strategy

Notable earnings before Thursday's open

Bruker Q1 2024 Earnings Preview

Bruker Corp (BRKR) has provided an announcement. Bruker Corporation has successfully completed its acquisition of ELITechGroup, a business previous...

Bruker Corp Announces Strategic Acquisition of ELITechGroup

Bruker Non-GAAP EPS of $0.53 beats by $0.07, revenue of $721.7M misses by $7.34M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Bruker (NASDAQ:<a href="https://investorplace.com/stock-quotes/brkr-stock-quote/">BRKR</a>) just reported results for the first quarter of 2024.<ul><li>Bruker reported earnings per share of 53 cents. This was above the analyst estimate for EPS of 46 cents.</li><li>The company reported revenue of $721.70 million.</li><li>This was 1.12% worse than the analyst estimate for revenue of $729.88 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/brkr-stock-earnings-bruker-for-q1-of-2024/">BRKR Stock Earnings: Bruker Beats EPS, Misses Revenue for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

BRKR Stock Earnings: Bruker Beats EPS, Misses Revenue for Q1 2024

Bruker Corporation 2024 Q1 - Results - Earnings Call Presentation

Bruker Corporation (BRKR) Q1 2024 Earnings Call Transcript

Bank of America Securities analyst Michael Ryskin maintained a Buy rating on Bruker (BRKR – Research Report) today. The company's shares opened tod...

Bank of America Securities Keeps Their Buy Rating on Bruker (BRKR)

10x Genomics stock slides amid German patent court ruling

ABUS

ACDVF

ACLLF

AGCO

AGIO

ALNY

AMKBY

APPN

APTV

ARES

ARHS

ATGFF

ATUS

AUPH

AVNS

AXGN

BPMC

CCRD

CDUAF

CGNX

CNHI

CPSH

CRTO

CYBR

DNNGY

DRVN

EDVMF

ENOV

EXLS

FLWS

FTDR

GERN

GMAB

HIPO

IDCC

INMD

IRMD

ITRI

NSTGQ

Press Releases

Bruker Advances Magnet Technology for Broader Adoption of NMR in Academic and Biopharma Research, and Process Analytical Technologies

Bruker Introduces Novel NMR Scientific Capabilities for Structural Biology Discoveries in Membrane Proteins and Protein Aggregates

Bruker to Acquire the NanoString Business in an Asset Deal

Bruker Announces Date and Time of First Quarter 2024 Earnings Release and Webcast

Bruker Further Enhances Clinical Microbiology & Infection Diagnostics Portfolio at ESCMID Global 2024 Conference

Bruker Reports First Quarter 2024 Financial Results

Bruker Completes Acquisition of Molecular Diagnostics Innovator ELITech

Bruker Completes Asset Acquisition of NanoString Business

German Federal Patent Court Invalidates Patent Asserted By 10x Genomics, Delivering Legal Win to NanoString and Bruker

Bruker Corporation to Host Investor Webinar on May 17, 2024

Agilent Technologies

AbCellera Biologics

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share